Soluble receptors for advanced glycation end products is associated with cardiac mortality among patients with stable ischemic heart disease: long-term follow-up of the LAERTES study

Background It has been suggested that circulating levels of the soluble receptor for advanced glycation end products (sRAGE) is a biomarker of underlying inflammation. There is limited data regarding its prognostic value in patients with stable coronary artery disease (CAD). We explored the long-term prognostic value of sRAGE levels on cardiac mortality in patients with CAD.Methods This is a retrospective analysis from LAERTES Study. Serum sRAGE levels were measured at baseline. sRAGE were quantified using DuoSetELISA kit. Primary endpoint was cardiac death and secondary endpoint the composite of non-fatal acute coronary syndrome (ACS) and ischemic stroke.Results Data were obtained from 800 patients (13% female, median age 62 years, median follow-up 6 years) of whom 76 died from cardiac death, 84 experienced ACS and 12 had ischemic stroke. Patients with cardiac death were older and had more comorbidities. sRAGE levels were predictive of cardiac death and remained an independent predictor for cardiac death (HR: 1.31, 95% CI: 1.03-1.67, p = 0.027) after adjustment for traditional risk factors and left ventricular ejection fraction. sRAGE levels could not predict the secondary endpoints.Conclusions Higher sRAGE levels are independently associated with cardiac mortality among CAD patients.